Adolescent and adult lymphoblastic leukaemia: Prognostic factors and response to treatment

Thirty consecutive patients with acute lymphoblastic leukaemia (ALL) who received treatment at Christchurch Hospital between 1972 and 1982 were reviewed. Complete remission (CR) was achieved in 80 per cent with a median survival of 65 weeks. Eleven of 30 patients had one or more of the following features—B cell ALL, a mediastinal mass, the Philadelphia chromosome (Ph1) and age 60 years or older at diagnosis. Although CR was obtained in 8 of these patients none survived three years. The remaining 19 patients were regarded as ‘good risk’ and treated by moderate intensity chemotherapy schedules. CR was obtained in 16 of these patients (84 per cent) and the estimated 5 year survival was 62 per cent with 6 patients remaining in remission from 5 to 9 years from diagnosis.

[1]  E. Thiel,et al.  Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. , 1984, Blood.

[2]  R. Mertelsmann,et al.  Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Carbone,et al.  Burkitt's lymphoma , 1981, The New England journal of medicine.

[4]  S. Rosenberg,et al.  Lymphoblastic lymphoma in adults: results of a pilot protocol. , 1981, Blood.

[5]  H. Gralnick,et al.  The Morphological Classification of Acute Lymphoblastic Leukaemia: Concordance among Observers and Clinical Correlations , 1981, British journal of haematology.

[6]  D. Pinkel The ninth annual david karnofsky lecture. Treatment of acute lymphocytic leukemia , 1979, Cancer.

[7]  J. E. Freeman,et al.  Combination chemotherapy for acute lymphoblastic leukaemia in adults. , 1978, British medical journal.

[8]  J. Ziegler Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience. , 1977, The New England journal of medicine.

[9]  T. Lister,et al.  Early central nervous system involvement in adults with acute non-myelogenous leukaemia. , 1977, British Journal of Cancer.

[10]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[11]  M. Greaves,et al.  Blast Crisis of Chronic Myeloid Leukaemia (CML): I. PRESENTATION SIMULATING ACUTE LYMPHOID LEUKAEMIA (ALL) , 1976, British journal of haematology.

[12]  B. Clarkson,et al.  Acute lymphoblastic leukemia in adults and children. Differences in response with similar therapeutic regimens , 1976, Cancer.

[13]  J. Bertino,et al.  Long‐term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy , 1975, Cancer.

[14]  Gottlieb Ja Combination chemotherapy: rationale for schedule selection and use of agents with independent toxicities in phase I and II clinical trials. , 1973 .

[15]  E. Freireich,et al.  Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. , 1972, Cancer chemotherapy reports.

[16]  C. Spurr,et al.  Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma. , 1969, Blood.